Form 4: FibroGen CEO Wettig Thane Reports Stock Transaction
SEC Form 4 Filing
CEO Wettig Thane of FibroGen, Inc. reports disposition of shares to cover tax obligations and discloses beneficial ownership.
Summary
- On June 6, 2024, Thane Wettig, CEO of FibroGen, Inc., reported a transaction involving the company's common stock.
- 2,255 shares were disposed of at a price of $1.19 to cover tax obligations related to vesting restricted stock units.
- Following the transaction, Wettig directly owns 446,301 shares of common stock and indirectly owns 1,000 shares through a spouse.
Sentiment
Score: 5
Explanation: This is a neutral report of a routine stock transaction. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive stock transactions and is typical for publicly traded companies.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on stakeholders.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of stock transaction |
| 06/07/2024 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.